Aurinia Pharmaceuticals Inc. [AUPH] Stock trading around $6.82 per share: What’s Next?

Aurinia Pharmaceuticals Inc. [NASDAQ: AUPH] traded at a high on 09/08/22, posting a 2.40 gain after which it closed the day’ session at $6.82. The company report on August 4, 2022 that Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored


Net revenue increased to $28.2 million for Q2 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS® (voclosporin) for 2022.

Continued increases in LUPKYNIS Patients on Treatment; Steady Conversion Rates and Payor Coverage.

The results of the trading session contributed to over 4045960 shares changing hands. Over the past one week, the price volatility of Aurinia Pharmaceuticals Inc. stands at 6.70% while the volatility over the past one month is 5.67%.

The market cap for AUPH stock reached $977.10 million, with 141.73 million shares outstanding and 132.67 million shares in the current float. Compared to the average trading volume of 2.78M shares, AUPH reached a trading volume of 4045960 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Aurinia Pharmaceuticals Inc. [AUPH]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUPH shares is $21.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUPH stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Aurinia Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 05, 2022. While these analysts kept the previous recommendation, Oppenheimer dropped their target price from $33 to $31. The new note on the price target was released on December 10, 2021, representing the official price target for Aurinia Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $32, while Oppenheimer analysts kept a Perform rating on AUPH stock. On January 25, 2021, analysts increased their price target for AUPH shares from 30 to 35.

The Average True Range (ATR) for Aurinia Pharmaceuticals Inc. is set at 0.48, with the Price to Sales ratio for AUPH stock in the period of the last 12 months amounting to 11.12. The Price to Book ratio for the last quarter was 2.28, with the Price to Cash per share for the same quarter was set at 2.73.

How has AUPH stock performed recently?

Aurinia Pharmaceuticals Inc. [AUPH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.34. With this latest performance, AUPH shares dropped by -16.11% in over the last four-week period, additionally sinking by -40.12% over the last 6 months – not to mention a drop of -64.95% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUPH stock in for the last two-week period is set at 29.27, with the RSI for the last a single of trading hit 25.91, and the three-weeks RSI is set at 32.79 for Aurinia Pharmaceuticals Inc. [AUPH]. The present Moving Average for the last 50 days of trading for this stock 9.11, while it was recorded at 6.97 for the last single week of trading, and 13.31 for the last 200 days.

Aurinia Pharmaceuticals Inc. [AUPH]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Aurinia Pharmaceuticals Inc. [AUPH] shares currently have an operating margin of -395.05 and a Gross Margin at +93.01. Aurinia Pharmaceuticals Inc.’s Net Margin is presently recorded at -396.81.

Return on Equity for this stock declined to -40.81, with Return on Assets sitting at -35.94.

Aurinia Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.30 and a Current Ratio set at 13.10.

Insider trade positions for Aurinia Pharmaceuticals Inc. [AUPH]

There are presently around $342 million, or 37.10% of AUPH stock, in the hands of institutional investors. The top three institutional holders of AUPH stocks are: BLACKROCK INC. with ownership of 7,811,743, which is approximately 327.475% of the company’s market cap and around 0.30% of the total institutional ownership; FMR LLC, holding 4,889,323 shares of the stock with an approximate value of $33.34 million in AUPH stocks shares; and NEA MANAGEMENT COMPANY, LLC, currently with $27.07 million in AUPH stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Aurinia Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 97 institutional holders increased their position in Aurinia Pharmaceuticals Inc. [NASDAQ:AUPH] by around 16,031,156 shares. Additionally, 75 investors decreased positions by around 8,657,389 shares, while 53 investors held positions by with 25,423,305 shares. The mentioned changes placed institutional holdings at 50,111,850 shares, according to the latest SEC report filing. AUPH stock had 44 new institutional investments in for a total of 3,111,847 shares, while 29 institutional investors sold positions of 2,758,395 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here